BIOA has been weak from its earlier highs in the $20s, and I'm really not sure why. They have an R&D day later this week, you can register here if you want: https://ir.bioagelabs.com/news-releases/news-release-details/bioage-host-rd-day-focused-nlrp3-inhibition-may-8-2026
BIOA easily has one of the most important and interesting assets in all of immunology right now and I don't say that often. The NLRP3 target is really well validated, by both BIOA and some competitors. VTYX was bought this year for $1.2b, a very small premium for what I think BIOA will go for in just 1 year's time (likely less). Here is the bullish pitch (I will share the risks below too): BIOA has better NLRP3, IL-6 lowering, hsCRP lowering than what VTYX showed, and is on par with what GLUE showed (which is not the same target, but similar). It also showed (in my opinion, some disagree), better results than The private company NodThera.
- The biggest catalyst is actually not BIOA's data - it is a study from NovoNordisk called ZEUS. ZEUS is a study of an Ziltivekimab in cardiovascular risk patients who also have kidney disease. It will read out probably in the 3rd quarter this year, but maybe sooner. It's hard to tell because it is driven by the number of events, not a certain timeframe.
If that is positive, that would imply that any study that BIOA runs in a similar setting would be as positive or better - and BIOA drug is ORAL. Not an injection. It's well tolerated.
- BIOA drug also has some good exposure in the eye. That is important because there are some anti-IL-6 drugs that are being studied in ocular diseases like wAMD, GA, etc. These are ENORMOUS markets - you may be familiar with Regeneron's Eylea which has been a monster blockbuster drug for a decade, selling billions. If IL-6 works well in the eye, again, NLRP3 oral drug will work as well.
If you combine the cardiovascular indications and ocular, you are looking at a $5b+ drug, easily, if not more. And BIOA has the best data out there.
CONCERNS? There is competition. Like I said - GLUE, VTYX (now LLY), NodThera, and a few other privates have NLRP3 inhibitors. But only GLUE has data that really matches up with BIOA. And GLUE is around 2x more expensive, mostly because they have a separate partnership with another asset.
Safety? So far the drug has been really well tolerated. The older NLRP3 drugs had really bad drug properties, low bioavailability or short half lifes, and some had liver toxicity. But BIOA avoids all this because their drug is completely different, chemically speaking and biologically.
I think BIOA should be fairly priced in the ~$25 range - without ANY additional data. WITH additional data, this will be above $40 - including if ZEUS is successful in the fall(ish) time frame this year.